Nanotoxicology

Frontiers of Nanoscience

Volumn 4, Issue 1, 2012, Pages 443-485

  Simón Vázquez, Rosana ^a   Peleteiro, Mercedes ^a   Lozano, Tamara ^a   González Fernández, África ^a   Casal, Amparo ^b  

^a UNIVERSITY OF VIGO   (Spain)

^b Paediatric Onco Hematology Azienda Ospedaliero Universitaria Meyer Children Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

NANOTOXICOLOGY;

NANOSTRUCTURED MATERIALS;

EID: 84872833669     PISSN: 18762778     EISSN: 1876276X     Source Type: Book Series    
DOI: 10.1016/B978-0-12-415769-9.00015-7     Document Type: Chapter

References (217)

1. Kreuter J. Nanoparticles-a historical perspective. Int J Pharm 2007;331(1):1-10.
2. Adlakha-Hutcheon G, Khaydarov R, Korenstein R, Varma R, Vaseashta A, Stamm H, et al. Nanomaterials, nanotechnology: applications, consumer products, and benefits. In: Linkov I, Steevens J, editors. Nanomaterials: risks and benefits. Netherlands: Springer; 2009. p. 195-207.
3. Zhang Z, Biskupek J, Kaiser U, Breus VV, Nienhaus GU, Wiedwald U, et al. Structural studies of nanoparticles with an objective-lens Cs-corrected Titan microscope. Microsc Microanal 2007;13:258-9.
4. Lechuga LM, Zinoviev K, Carrascosa LG, Moreno M. Nanodevices for biosensing: design, fabrication and applications. Nanotechnol Life Sci 2007;317-44.
5. Rosi NL, Mirkin CA. Nanostructures in biodiagnostics. Chem Rev 2005;105(4):1547-62.
6. Chaudhry Q, Scotter M, Blackburn J, Ross B, Boxall A, Castle L, et al. Applications and implications of nanotechnologies for the food sector. Food Addit Contam Part A 2008;25 (3):241-58.
7. Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother 2006;7(8):1041-53.
8. Song Y, Li X, Du X. Exposure to nanoparticles is related to pleural effusion, pulmonary fibrosis and granuloma. Eur Respir J 2009;34(3):559-67.
9. Franca A, Pelaz B, Moros M, Sanchez-Espinel C, Hernandez A, Fernandez-Lopez C, et al. Sterilization matters: consequences of different sterilization techniques on gold nanoparticles. Small 2010;6(1):89-95.
10. Mossman BT, Churg A. Mechanisms in the pathogenesis of asbestosis and silicosis. Am J Respir Crit Care Med 1998;157(5):1666-80.
11. Jomova K, Valko M. Advances in metal-induced oxidative stress and human disease. Toxicology 2011;283(2-3):65-87.
12. Medina C, Santos-Martinez MJ, Radomski A, Corrigan OI, Radomski MW. Nanoparticles: pharmacological and toxicological significance. Br J Pharmacol 2007;150(5):552-8.
13. Díaz B, Sánchez-Espinel C, Arruebo M, Faro J, de Miguel E, Magadán S, et al. Assessing methods for blood cell cytotoxic responses to inorganic nanoparticles and nanoparticle aggregates. Small 2008;4(11):2025-34.
14. Owens 3rd DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 2006;307(1):93-102.
15. Aggarwal P, Hall JB, McLeland CB, Dobrovolskaia MA, McNeil SE. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev 2009;61(6):428-37.
16. Dobrovolskaia MA, McNeil SE. Immunological properties of engineered nanomaterials. Nat Nanotechnol 2007;2(8):469-78.
17. Zolnik BS, González-Fernández ÁSadrieh N, Dobrovolskaia MA. Minireview: nanoparticles and the immune system. Endocrinology 2010;151(2):458-65.
18. Arruebo M, Valladares M, González-Fernández Á. Antibody-conjugated nanoparticles for biomedical applications. J Nanomater 2009; Article ID 439389, 24 pp.
19. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces 2010;75(1):1-18.
20. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 2008;83 (5):761-9.
21. Bangham AD, Horne RW. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. J Mol Biol 1964;8: 660-8.
22. Barani H, Montazer M. A review on applications of liposomes in textile processing. J Liposome Res 2008;18(3):249-62.
23. Dokka S, Toledo D, Shi X, Castranova V, Rojanasakul Y. Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes. Pharm Res 2000;17(5):521-5.
24. Zbinden G, Wunderli-Allenspach H, Grimm L. Assessment of thrombogenic potential of liposomes. Toxicology 1989;54(3):273-80.
25. Plank C, Mechtler K, Szoka Jr. FC, Wagner E. Activation of the complement system by synthetic DNA complexes: a potential barrier for intravenous gene delivery. Hum Gene Ther 1996;7(12):1437-46.
26. Tran MA, Watts RJ, Robertson GP. Use of liposomes as drug delivery vehicles for treatment of melanoma. Pigment Cell Melanoma Res 2009;22(4):388-99.
27. Santel A, Aleku M, Keil O, Endruschat J, Esche V, Durieux B, et al. RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy. Gene Ther 2006;13(18):1360-70.
28. Dadashzadeh S, Mirahmadi N, Babaei MH, Vali AM. Peritoneal retention of liposomes: effects of lipid composition, PEG coating and liposome charge. J Control Release 2010; 148(2):177-86.
29. Christensen D, Korsholm KS, Andersen P, Agger EM. Cationic liposomes as vaccine adjuvants. Expert Rev Vaccines 2011;10(4):513-21.
30. Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci 2009;30(11):592-9.
31. Gwinn WM, Kapita MC, Wang PM, Cesta MF, Martin WJ. Synthetic liposomes are protective from bleomycin-induced lung toxicity. Am J Physiol Lung Cell Mol Physiol 2011;301 (2):L207-L217.
32. Leite EA, Giuberti Cdos S, Wainstein AJ, Wainstein AP, Coelho LG, Lana AM, et al. Acute toxicity of long-circulating and pH-sensitive liposomes containing cisplatin in mice after intraperitoneal administration. Life Sci 2009;84(19-20):641-9.
33. Chang RS, Kim J, Lee HY, Han SE, Na J, Kim K, et al. Reduced dose-limiting toxicity of intraperitoneal mitoxantrone chemotherapy using cardiolipin-based anionic liposomes. Nanomedicine 2010;6(6):769-76.
34. Stover TC, Sharma A, Robertson GP, Kester M. Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma. Clin Cancer Res 2005;11(9):3465-74.
35. Mullauer FB, van Bloois L, Daalhuisen JB, Ten Brink MS, Storm G, Medema JP, et al. Betulinic acid delivered in liposomes reduces growth of human lung and colon cancers in mice without causing systemic toxicity. Anticancer Drugs 2011;22(3):223-33.
36. Sawant RR, Torchilin VP. Liposomes as 'smart' pharmaceutical nanocarriers. Soft Matter 2010;6(17):4026-44.
37. Mudshinge SR, Deore AB, Patil S, Bhalgat CM. Nanoparticles: emerging carriers for drug delivery. Saudi Pharm J 2011;19(3):129-41.
38. Olbrich C, Muller RH, Tabatt K, Kayser O, Schulze C, Schade R. Stable biocompatible adjuvants-a new type of adjuvant based on solid lipid nanoparticles: a study on cytotoxicity, compatibility and efficacy in chicken. Altern Lab Anim 2002;30(4):443-58.
39. Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 2004;56(9):1257-72.
40. Gualbert J, Shahgaldian P, Coleman AW. Interactions of amphiphilic calix[4]arene-based solid lipid nanoparticles with bovine serum albumin. Int J Pharm 2003;257:69-73.
41. Patel TD, Parikh BN, Gothi GD, Dave JB, Patel CN. A review on pharmaceutical and non pharmaceutical applications on dendrimer. J Global Pharm Technol 2010;2(2):5-17.
42. Brauge L, Vériot G, Franc G, Deloncle R, Caminade A-M, Majoral J-P. Synthesis of phosphorus dendrimers bearing chromophoric end groups: toward organic blue light-emitting diodes. Tetrahedron 2006;62(51):11891-9.
43. Kunzmann A, Andersson B, Thurnherr T, Krug H, Scheynius A, Fadeel B. Toxicology of engineered nanomaterials: focus on biocompatibility, biodistribution and biodegradation. Biochim Biophys Acta 2011;1810(3):361-73.
44. Chen H-T, Neerman MF, Parrish AR, Simanek EE. Cytotoxicity, hemolysis, and acute in vivo toxicity of dendrimers based on melamine, candidate vehicles for drug delivery. J Am Chem Soc 2004;126(32):10044-8.
45. Bhadra D, Yadav AK, Bhadra S, Jain NK. Glycodendrimeric nanoparticulate carriers of primaquine phosphate for liver targeting. Int J Pharm 2005;295(1-2):221-33.
46. Agashe HB, Dutta T, Garg M, Jain NK. Investigations on the toxicological profile of functionalized fifth-generation poly (propylene imine) dendrimer. J Pharm Pharmacol 2006;58 (11):1491-8.
47. Jain K, Kesharwani P, Gupta U, Jain NK. Dendrimer toxicity: let's meet the challenge. Int J Pharm 2010;394(1-2):122-42.
48. Roberts JC, Bhalgat MK, Zera RT. Preliminary biological evaluation of polyamidoamine (PAMAM) Starburst dendrimers. J Biomed Mater Res 1996;30(1):53-65.
49. Neerman MF, Chen HT, Parrish AR, Simanek EE. Reduction of drug toxicity using dendrimers based on melamine. Mol Pharm 2004;1(5):390-3.
50. Malik N, Wiwattanapatapee R, Klopsch R, Lorenz K, Frey H, Weener JW, et al. Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. J Control Release 2000;65(1-2):133-48.
51. Prego C, Paolicelli P, Diaz B, Vicente S, Sanchez A, Gonzalez-Fernandez A, et al. Chitosanbased nanoparticles for improving immunization against hepatitis B infection. Vaccine 2010;28(14):2607-14.
52. Hong D, et al. Bioconjugated PLGA-4-arm-PEG branched polymeric nanoparticles as novel tumor targeting carriers. Nanotechnology 2011;22(16):165101.
53. Kalaria D, Sharma G, Beniwal V, Ravi Kumar M. Design of biodegradable nanoparticles for oral delivery of doxorubicin: in vivo; pharmacokinetics and toxicity studies in rats. Pharm Res 2009;26(3):492-501.
54. Uhrich KE, Cannizzaro SM, Langer RS, Shakesheff KM. Polymeric systems for controlled drug release. Chem Rev 1999;99(11):3181-98.
55. Wang C, Ge Q, Ting D, Nguyen D, Shen HR, Chen J, et al. Molecularly engineered poly (ortho ester) microspheres for enhanced delivery of DNA vaccines. Nat Mater 2004;3 (3):190-6.
56. Katti DS, Lakshmi S, Langer R, Laurencin CT. Toxicity, biodegradation and elimination of polyanhydrides. Adv Drug Deliv Rev 2002;54(7):933-61.
57. Itaka K, Ishii T, Hasegawa Y, Kataoka K. Biodegradable polyamino acid-based polycations as safe and effective gene carrier minimizing cumulative toxicity. Biomaterials 2010;31 (13):3707-14.
58. Silva GA, Ducheyne P, Reis RL. Materials in particulate form for tissue engineering. 1. Basic concepts. J Tissue Eng Regen Med 2007;1(1):4-24.
59. Maeda M, Tani S, Sano A, Fujioka K. Microstructure and release characteristics of the minipellet, a collagen-based drug delivery system for controlled release of protein drugs. J Control Release 1999;62(3):313-24.
60. Oyarzun-Ampuero FA, Goycoolea FM, Torres D, Alonso MJ. A new drug nanocarrier consisting of polyarginine and hyaluronic acid. Eur J Pharm Biopharm 2011;79(1):54-7.
61. Marques AP, Reis RL, Hunt JA. The biocompatibility of novel starch-based polymers and composites: in vitro studies. Biomaterials 2002;23(6):1471-8.
62. Tiyaboonchai W, Woiszwillo J, Middaugh CR. Formulation and characterization of DNApolyethylenimine- dextran sulfate nanoparticles. Eur J Pharm Sci 2003;19(4):191-202.
63. Bertholon I, Vauthier C, Labarre D. Complement activation by core-shell poly(isobutylcyanoacrylate)- polysaccharide nanoparticles: influences of surface morphology, length, and type of polysaccharide. Pharm Res 2006;23(6):1313-23.
64. Loh JW, Yeoh G, Saunders M, Lim LY. Uptake and cytotoxicity of chitosan nanoparticles in human liver cells. Toxicol Appl Pharmacol 2010;249(2):148-57.
65. Wedmore I, McManus JG, Pusateri AE, Holcomb JB. A special report on the chitosan-based hemostatic dressing: experience in current combat operations. J Trauma 2006;60(3):655-8.
66. Kean T, Thanou M. Biodegradation, biodistribution and toxicity of chitosan. Adv Drug Deliv Rev 2010;62(1):3-11.
67. Grillo R, de Melo NFS, de Araújo DR, de Paula E, Rosa AH, Fraceto LF. Polymeric alginate nanoparticles containing the local anesthetic bupivacaine. J Drug Target 2010;18(9):688-99.
68. Gazori T, Haririan I, Fouladdel S, Namazi A, Nomani A, Azizi E. Inhibition of EGFR expression with chitosan/alginate nanoparticles encapsulating antisense oligonucleotides in T47D cell line using RT-PCR and immunocytochemistry. Carbohydr Polym 2010;80(4):1042-7.
69. Reis ECC, Borges APB, Fonseca CC, Martinez MMM, Eleotério RB, Morato GO, et al. Biocompatibility, osteointegration, osteoconduction, and biodegradation of a hydroxyapatitepolyhydroxybutyrate composite. Braz Arch Biol Technol 2010;53:817-26.
70. Carlo EC, Borges AP, Del Carlo RJ, Martinez MM, Oliveira PM, Morato GO, et al. Comparison of in vivo properties of hydroxyapatite-polyhydroxybutyrate composites assessed for bone substitution. J Craniofac Surg 2009;20(3):853-9.
71. Unverdorben M, Spielberger A, Schywalsky M, Labahn D, Hartwig S, Schneider M, et al. A polyhydroxybutyrate biodegradable stent: preliminary experience in the rabbit. Cardiovasc Intervent Radiol 2002;25(2):127-32.
72. Alves EG, Rezende CM, Serakides R, Pereira MD, Rosado IR. Orthopedic implant of a polyhydroxybutyrate (PHB) and hydroxyapatite composite in cats. J Feline Med Surg 2011;13(8):546-52.
73. Oh JK, Drumright R, Siegwart DJ, Matyjaszewski K. The development of microgels/nanogels for drug delivery applications. Prog Polym Sci 2008;33(4):448-77.
74. Ganta C, Shi A, Battina SK, Pyle M, Rana S, Hua DH, et al. Combination of nanogel polyethylene glycol-polyethylenimine and 6(hydroxymethyl)-1,4-anthracenedione as an anticancer nanomedicine. J Nanosci Nanotechnol 2008;8(5):2334-40.
75. Gota C, Okabe K, Funatsu T, Harada Y, Uchiyama S. Hydrophilic fluorescent nanogel thermometer for intracellular thermometry. J Am Chem Soc 2009;131(8):2766-7.
76. Oishi M, Nagasaki Y. Synthesis, characterization, and biomedical applications of core-shell-type stimuli-responsive nanogels-nanogel composed of poly[2-(N, N-diethylamino)ethyl methacrylate] core and PEG tethered chains. React Funct Polym 2007;67(11):1311-29.
77. Sasaki Y, Akiyoshi K. Nanogel engineering for new nanobiomaterials: from chaperoning engineering to biomedical applications. Chem Rec 2010;10(6):366-76.
78. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 2008;132(3):171-83.
79. Garber K. Improved paclitaxel formulation hints at new chemotherapy approach. J Natl Cancer Inst 2004;96(2):90-1.
80. Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A, et al. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res 2005;11(11):4136-43.
81. John TA, Vogel SM, Tiruppathi C, Malik AB, Minshall RD. Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am J Physiol Lung Cell Mol Physiol 2003;284(1):L187-L196.
82. Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albuminbound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 2006;12(4):1317-24.
83. Lu W, Wan J, She Z, Jiang X. Brain delivery property and accelerated blood clearance of cationic albumin conjugated pegylated nanoparticle. J Control Release 2007;118(1):38-53.
84. Zensi A, Begley D, Pontikis C, Legros C, Mihoreanu L, Wagner S, et al. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. J Control Release 2009;137(1):78-86.
85. Lassus M, Scott D, Leyland-Jones B. Allergic reactions associated with cremophor containing antineoplastics. Proc Annu Meet Am Soc Clin Oncol 1985;4:268.
86. Nolte H, Carstensen H, Hertz H. VM-26 (teniposide)-induced hypersensitivity and degranulation of basophils in children. Am J Pediatr Hematol Oncol 1988;10:308-12.
87. Kris MG, O'Connell JP, Gralla RJ, Wertheim MS, Parente RM, Schiff PB, et al. Phase I trial of taxol given as a 3-hour infusion every 21 days. Cancer Treat Rep 1986;70(5):605-7.
88. Szebeni J, Muggia FM, Alving CR. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst 1998;90 (4):300-6.
89. Szebeni J. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology 2005;216(2-3):106-21.
90. Hunter RL, McNicholl J, Lal AA. Mechanisms of action of nonionic block copolymer adjuvants. AIDS Res Hum Retroviruses 1994;10(Suppl. 2):S95-S98.
91. Terwogt JM, Nuijen B, Huinink WW, Beijnen JH. Alternative formulations of paclitaxel. Cancer Treat Rev 1997;23(2):87-95.
92. Lundberg BB. A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (Taxol). J Pharm Pharmacol 1997;49(1):16-21.
93. Paradis R, Page M. New active paclitaxel amino acids derivatives with improved water solubility. Anticancer Res 1998;18(4):2711-6.
94. Scripture CD, Figg WD, Sparreboom A. Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy. Ther Clin Risk Manag 2005;1(2):107-14.
95. Moghimi SM, Hunter AC, Dadswell CM, Savay S, Alving CR, Szebeni J. Causative factors behind poloxamer 188 (Pluronic F68, Flocor)-induced complement activation in human sera. A protective role against poloxamer-mediated complement activation by elevated serum lipoprotein levels. Biochim Biophys Acta 2004;1689(2):103-13.
96. Hall MD, Mellor HR, Callaghan R, Hambley TW. Basis for design and development of platinum( IV) anticancer complexes. J Med Chem 2007;50(15):3403-11.
97. Gao J, Liang G, Zhang B, Kuang Y, Zhang X, Xu B. FePtCoS(2) yolk-shell nanocrystals as a potent agent to kill HeLa cells. J Am Chem Soc 2007;129(5):1428-33.
98. Schwenk MH. Ferumoxytol: a new intravenous iron preparation for the treatment of iron deficiency anemia in patients with chronic kidney disease. Pharmacotherapy 2010;30(1):70-9.
99. Auerbach M, Silberstein PT, Webb RT, Averyanova S, Ciuleanu TE, Shao J, et al. Darbepoetin alfa 300 or 500 mug once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. Am J Hematol 2010;85(9):655-63.
100. Bulte JW, Kraitchman DL, Mackay AM, Pittenger MF. Chondrogenic differentiation of mesenchymal stem cells is inhibited after magnetic labeling with ferumoxides. Blood 2004;104(10):3410-2 author reply 3412-3.
101. Arbab AS, Yocum GT, Rad AM, Khakoo AY, Fellowes V, Read EJ, et al. Labeling of cells with ferumoxides-protamine sulfate complexes does not inhibit function or differentiation capacity of hematopoietic or mesenchymal stem cells. NMR Biomed 2005;18(8):553-9.
102. Farrell E, Wielopolski P, Pavljasevic P, van Tiel S, Jahr H, Verhaar J, et al. Effects of iron oxide incorporation for long term cell tracking on MSC differentiation in vitro and in vivo. Biochem Biophys Res Commun 2008;369(4):1076-81.
103. Fan C, Gao W, Chen Z, Fan H, Li M, Deng F. Tumor selectivity of stealth multi-functionalized superparamagnetic iron oxide nanoparticles. Int J Pharm 2011;404(1-2):180-90.
104. Tang C, Russell PJ, Martiniello-Wilks R, Rasko JE, Khatri A. Concise review: nanoparticles and cellular carriers-allies in cancer imaging and cellular gene therapy? Stem Cells 2010;28 (9):1686-702.
105. Lewinski N, Colvin V, Drezek R. Cytotoxicity of nanoparticles. Small 2008;4(1):26-49.
106. Kato S, Taira H, Aoshima H, Saitoh Y, Miwa N. Clinical evaluation of fullerene-C60 dissolved in squalane for anti-wrinkle cosmetics. J Nanosci Nanotechnol 2010;10(10):6769-74.
107. Marano F, Hussain S, Rodrigues-Lima F, Baeza-Squiban A, Boland S. Nanoparticles: molecular targets and cell signalling. Arch Toxicol 2011;85(7):733-41.
108. Lundqvist M, Stigler J, Elia G, Lynch I, Cedervall T, Dawson KA. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc Natl Acad Sci USA 2008;105(38):14265-70.
109. Nel AE, Madler L, Velegol D, Xia T, Hoek EM, Somasundaran P, et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater 2009;8(7):543-57.
110. Deng ZJ, Liang M, Monteiro M, Toth I, Minchin RF. Nanoparticle-induced unfolding of fibrinogen promotes Mac-1 receptor activation and inflammation. Nat Nanotechnol 2011;6 (1):39-44.
111. Mcintyre T. Phytoremediation of heavy metals from soils. In: Tsao D, editor. Phytoremediation. Berlin/Heidelberg: Springer; 2003. p. 97-123.
112. Valko M, Morris H, Cronin MT. Metals, toxicity and oxidative stress. Curr Med Chem 2005;12(10):1161-208.
113. Harbison RD. Hamilton & Hardy's industrial toxicology. 5th ed. St. Louis, MO: Year Book Medical; 1998.
114. Klaassen CD. Casarett and Doull's toxicology: the basic science of poisons. 7th ed. New York, USA: McGraw-Hill; 2008.
115. Stacey NH, Winder C. Occupational toxicology. 1st ed. London: Taylor & Francis Group; 1995.
116. Schmidt M, Raghavan B, Muller V, Vogl T, Fejer G, Tchaptchet S, et al. Crucial role for human Toll-like receptor 4 in the development of contact allergy to nickel. Nat Immunol 2010;11(9):814-9.
117. Zahir F, Rizwi SJ, Haq SK, Khan RH. Low dose mercury toxicity and human health. Environ Toxicol Pharmacol 2005;20(2):351-60.
118. Baruthio F. Toxic effects of chromium and its compounds. Biol Trace Elem Res 1992;32 (1):145-53.
119. Costa M, Klein CB. Toxicity and carcinogenicity of chromium compounds in humans. Crit Rev Toxicol 2006;36(2):155-63.
120. Papanikolau Nikolas C, Hatzidaki Eleftheria G, Stamatis B, Tzanakakis George N, Tsatsakis Aristidis M. Lead toxicity update. A brief review. Med Sci Monit 2005;11:329-36.
121. Michael FH. Arsenic toxicity and potential mechanisms of action. Toxicol Lett 2002;133 (1):1-16.
122. Godt J, Scheidig F, Grosse-Siestrup C, Esche V, Brandenburg P, Reich A, et al. The toxicity of cadmium and resulting hazards for human health. J Occup Med Toxicol 2006;1 (1):22.
123. Otsuki T, Maeda M, Murakami S, Hayashi H, Miura Y, Kusaka M, et al. Immunological effects of silica and asbestos. Cell Mol Immunol 2007;4(4):261-8.
124. Cagle PT, Allen TC. Asbestosis and silicosis. In: Zander DS, et al. editors. Molecular pathology of lung diseases. New York: Springer; 2008. p. 658-62.
125. Iyer R, Hamilton RF, Li L, Holian A. Silica-induced apoptosis mediated via scavenger receptor in human alveolar macrophages. Toxicol Appl Pharmacol 1996;141(1):84-92.
126. Hamilton RF, Thakur SA, Mayfair JK, Holian A. MARCO mediates silica uptake and toxicity in alveolar macrophages from C57BL/6 mice. J Biol Chem 2006;281 (45):34218-26.
127. Arredouani M, Yang Z, Ning Y, Qin G, Soininen R, Tryggvason K, et al. The scavenger receptor MARCO Is required for lung defense against pneumococcal pneumonia and inhaled particles. J Exp Med 2004;200(2):267-72.
128. Chao SK, Hamilton RF, Pfau JC, Holian A. Cell surface regulation of silica-induced apoptosis by the SR-A scavenger receptor in a murine Lung macrophage cell line (MH-S). Toxicol Appl Pharmacol 2001;174(1):10-6.
129. Hamilton RF, de Villiers WJS, Holian A. Class A type II scavenger receptor mediates silicainduced apoptosis in Chinese hamster ovary cell line. Toxicol Appl Pharmacol 2000;162 (2):100-6.
130. Beamer CA, Holian A. Scavenger receptor class A type I/II (CD204) null mice fail to develop fibrosis following silica exposure. Am J Physiol Lung Cell Mol Physiol 2005;289 (2):L186-L195.
131. Franca A, Aggarwal P, Barsov EV, Kozlov SV, Dobrovolskaia MA, González-Fernández Á. Macrophage scavenger receptor A mediates the uptake of gold colloids by macrophages in vitro. Nanomedicine (Lond) 2011;6(7):1175-88.
132. Tiwari R. Biomarkers of silicosis: potential candidates. Indian J Occup Environ Med 2005;9 (3):103-6.
133. Tripathi S, Pandey H, Paul B. Overview of cytokines and receptors in Silicosis. J Appl Pharm Sci 2011;01(05):01-05.
134. Trojanowicz M. Analytical applications of carbon nanotubes: a review. TrAC Trends Anal Chem 2006;25(5):480-9.
135. Makar JM, Beaudoin JJ. Carbon nanotubes and their application in the construction industry. Proceedings of 1st International Symposium on Nanotechnology in Construction. 2003;331-41.
136. Popov VN. Carbon nanotubes: properties and application. Mat Sci Eng R Rep 2004;43 (3):61-102.
137. Sanles-Sobrido M, Rodriguez-Lorenzo L, Lorenzo-Abalde S, Gonzalez-Fernandez A, Correa-Duarte MA, Alvarez-Puebla RA, et al. Label-free SERS detection of relevant bioanalytes on silver-coated carbon nanotubes: the case of cocaine. Nanoscale 2009;1(1):153-8.
138. Chen B, Zhang H, Zhai C, Du N, Sun C, Xue J, et al. Carbon nanotube-based magnetic-fluorescent nanohybrids as highly efficient contrast agents for multimodal cellular imaging. J Mater Chem 2010;20(44):9895-902.
139. Crosera M, Bovenzi M, Maina G, Adami G, Zanette C, Florio C, et al. Nanoparticle dermal absorption and toxicity: a review of the literature. Int Arch Occup Environ Health 2009;82 (9):1043-55.
140. Shvedova A, Castranova V, Kisin E, Schwegler-Berry D, Murray A, Gandelsman V, et al. Exposure to carbon nanotube material: assessment of nanotube cytotoxicity using human keratinocyte cells. J Toxicol Environ Health A 2003;66(20):1909-26.
141. Bekyarova E, Ni Y, Malarkey EB, Montana V, McWilliams JL, Haddon RC, et al. Applications of carbon nanotubes in biotechnology and biomedicine. J Biomed Nanotechnol 2005;1 (1):3-17.
142. Sayes CM, Liang F, Hudson JL, Mendez J, Guo W, Beach JM, et al. Functionalization density dependence of single-walled carbon nanotubes cytotoxicity in vitro. Toxicol Lett 2006;161(2):135-42.
143. Manna SK, Sarkar S, Barr J, Wise K, Barrera EV, Jejelowo O, et al. Single-walled carbon nanotube induces oxidative stress and activates nuclear transcription factor-kB in human keratinocytes. Nano Lett 2005;5(9):1676-84.
144. Zhang LW, Zeng L, Barron AR, Monteiro-Riviere NA. Biological interactions of functionalized single-wall carbon nanotubes in human epidermal keratinocytes. Int J Toxicol 2007;26 (2):103-13.
145. Sargent LM, Shvedova AA, Hubbs AF, Salisbury JL, Benkovic SA, Kashon ML, et al. Induction of aneuploidy by single-walled carbon nanotubes. Environ Mol Mutagen 2009;50(8):708-17.
146. Ding L, Stilwell J, Zhang T, Elboudwarej O, Jiang H, Selegue JP, et al. Molecular characterization of the cytotoxic mechanism of multiwall carbon nanotubes and nano-onions on human skin fibroblast. Nano Lett 2005;5(12):2448-64.
147. Teeguarden JG, Webb-Robertson B-J, Waters KM, Murray AR, Kisin ER, Varnum SM, et al. Comparative proteomics and pulmonary toxicity of instilled single-walled carbon nanotubes, crocidolite asbestos, and ultrafine carbon black in mice. Toxicol Sci 2011;120(1):123-35.
148. Morimoto Y, Hirohashi M, Ogami A, Oyabu T, Myojo T, Todoroki M. et al. Nanotoxicology: Pulmonary toxicity of well-dispersed multi-wall carbon nanotubes following inhalation and intratracheal instillation; 2011 Article ID 594912.
149. Kobayashi N, Naya M, Ema M, Endoh S, Maru J, Mizuno K, et al. Biological response and morphological assessment of individually dispersed multi-wall carbon nanotubes in the lung after intratracheal instillation in rats. Toxicology 2010;276(3):143-53.
150. Reddy ARN, Reddy YN, Krishna DR, Himabindu V. Pulmonary toxicity assessment of multiwalled carbon nanotubes in rats following intratracheal instillation. Environ Toxicol 2012;27(4):211-9.
151. Roda E, Coccini T, Acerbi D, Barni S, Vaccarone R, Manzo L. Comparative pulmonary toxicity assessment of pristine and functionalized multi-walled carbon nanotubes intratracheally instilled in rats: morphohistochemical evaluations. Histol Histopathol 2011;26(3):357-67.
152. Salvador-Morales C, Flahaut E, Sim E, Sloan J, Green MLH, Sim RB. Complement activation and protein adsorption by carbon nanotubes. Mol Immunol 2006;43(3):193-201.
153. Dumortier H, Lacotte S, Pastorin G, Marega R, Wu W, Bonifazi D, et al. Functionalized carbon nanotubes are non-cytotoxic and preserve the functionality of primary immune cells. Nano Lett 2006;6(7):1522-8.
154. Markovic Z, Trajkovic V. Biomedical potential of the reactive oxygen species generation and quenching by fullerenes (C60). Biomaterials 2008;29(26):3561-73.
155. Kroto HW, Heath JR, O'Brien SC, Curl RF, Smalley RE. C60: buckminsterfullerene. Nature 1985;318(14):162-3.
156. Isaacson CW, Kleber M, Field JA. Quantitative analysis of fullerene nanomaterials in environmental systems: a critical review. Environ Sci Technol 2009;43(17):6463-74.
157. Aschberger K, Johnston HJ, Stone V, Aitken RJ, Tran CL, Hankin SM, et al. Review of fullerene toxicity and exposure-appraisal of a human health risk assessment, based on open literature. Regul Toxicol Pharmacol 2010;58(3):455-73.
158. Sayes CM, Fortner JD, Guo W, Lyon D, Boyd AM, Ausman KD, et al. The differential cytotoxicity of water-soluble fullerenes. Nano Lett 2004;4(10):1881-7.
159. Sayes CM, Gobin AM, Ausman KD, Mendez J, West JL, Colvin VL. Nano-C60 cytotoxicity is due to lipid peroxidation. Biomaterials 2005;26(36):7587-95.
160. Porter AE, Muller K, Skepper J, Midgley P, Welland M. Uptake of C60 by human monocyte macrophages, its localization and implications for toxicity: studied by high resolution electron microscopy and electron tomography. Acta Biomater 2006;2(4):409-19.
161. Johnston HJ, Hutchison GR, Christensen FM, Aschberger K, Stone V. The biological mechanisms and physicochemical characteristics responsible for driving fullerene toxicity. Toxicol Sci 2010;114(2):162-82.
162. Isakovic A, Markovic Z, Todorovic-Markovic B, Nikolic N, Vranjes-Djuric S, Mirkovic M, et al. Distinct cytotoxic mechanisms of pristine versus hydroxylated fullerene. Toxicol Sci 2006;91(1):173-83.
163. Chen HHC, Yu C, Ueng TH, Chen S, Chen BJ, Huang KJ, et al. Acute and subacute toxicity study of water-soluble polyalkylsulfonated C60 in rats. Toxicol Pathol 1998;26(1):143-51.
164. Mori T, Takada H, Ito S, Matsubayashi K, Miwa N, Sawaguchi T. Preclinical studies on safety of fullerene upon acute oral administration and evaluation for no mutagenesis. Toxicology 2006;225(1):48-54.
165. Moussa F, Trivin F, Céolin R, Hadchouel M, Sizaret PY, Greugny V, et al. Early effects of C60 administration in Swiss mice: a preliminary account for in vivo C60 toxicity. Fullerene Sci. Technol. 1996;4(1):21-9.
166. Gharbi N, Pressac M, Hadchouel M, Szwarc H, Wilson SR, Moussa F. [60]Fullerene is a powerful antioxidant in vivo with no acute or subacute toxicity. Nano Lett 2005;5(12):2578-85.
167. Yamago S, Tokuyama H, Nakamura E, Kikuchi K, Kananishi S, Sueki K, et al. In vivo biological behavior of a water-miscible fullerene: 14C labeling, absorption, distribution, excretion and acute toxicity. Chem Biol 1995;2(6):385-9.
168. Kubota R, Tahara M, Shimizu K, Sugimoto N, Hirose A, Nishimura T. Time-dependent variation in the biodistribution of C60 in rats determined by liquid chromatography-tandem mass spectrometry. Toxicol Lett 2011;206(2):172-7.
169. Baker GL, Gupta A, Clark ML, Valenzuela BR, Staska LM, Harbo SJ, et al. Inhalation toxicity and lung toxicokinetics of C60 fullerene nanoparticles and microparticles. Toxicol Sci 2008;101(1):122-31.
170. Fujita K, Morimoto Y, Ogami A, Myojyo T, Tanaka I, Shimada M, et al. Gene expression profiles in rat lung after inhalation exposure to C60 fullerene particles. Toxicology 2009;258(1):47-55.
171. Totsuka Y, Kato T, Masuda S-i, Ishino K, Matsumoto Y, Goto S, et al. In Vitro and in vivo genotoxicity induced by fullerene (C60) and kaolin. Genes Environ 2011;33(1):14-20.
172. Benn TM, Westerhoff P, Herckes P. Detection of fullerenes (C60 and C70) in commercial cosmetics. Environ Pollut 2011;159(5):1334-42.
173. Rouse JG, Yang J, Ryman-Rasmussen JP, Barron AR, Monteiro-Riviere NA. Effects of mechanical flexion on the penetration of fullerene amino acid-derivatized peptide nanoparticles through skin. Nano Lett 2006;7(1):155-60.
174. Nielsen GD, Roursgaard M, Jensen KA, Poulsen SS, Larsen ST. In vivo biology and toxicology of fullerenes and their derivatives. Basic Clin Pharmacol Toxicol 2008;103(3):197-208.
175. Xia XR, Monteiro-Riviere NA, Riviere JE. Skin penetration and kinetics of pristine fullerenes (C60) topically exposed in industrial organic solvents. Toxicol Appl Pharmacol 2010;242(1):29-37.
176. Usenko CY, Harper SL, Tanguay RL. In vivo evaluation of carbon fullerene toxicity using embryonic zebrafish. Carbon 2007;45(9):1891-8.
177. Michalet X, Pinaud FF, Bentolila LA, Tsay JM, Doose S, Li JJ, et al. Quantum dots for live cells, in vivo imaging, and diagnostics. Science 2005;307(5709):538-44.
178. Reimann SM, Manninen M. Electronic structure of quantum dots. Rev Mod Phys 2002;74 (4):1283.
179. Gao X, Cui Y, Levenson RM, Chung LWK, Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 2004;22(8):969-76.
180. Chang H, Lv X, Zhang H, Li J. Quantum dots sensitized graphene: in situ growth and application in photoelectrochemical cells. Electrochem Commun 2010;12(3):483-7.
181. Mancini MC, Kairdolf BA, Smith AM, Nie S. Oxidative quenching and degradation of polymer-encapsulated quantum dots: new insights into the long-term fate and toxicity of nanocrystals in vivo. J Am Chem Soc 2008;130(33):10836-7.
182. Jiang W, Papa E, Fischer H, Mardyani S, Chan WCW. Semiconductor quantum dots as contrast agents for whole animal imaging. Trends Biotechnol 2004;22(12):607-9.
183. Kim S, Lim YT, Soltesz EG, De Grand AM, Lee J, Nakayama A, et al. Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping. Nat Biotechnol 2004;22(1):93-7.
184. Åkerman ME, Chan WCW, Laakkonen P, Bhatia SN, Ruoslahti E. Nanocrystal targeting in vivo. Proc Natl Acad Sci USA 2002;99(20):12617-21.
185. Hardman R. A toxicologic review of quantum dots: toxicity depends on physicochemical and environmental factors. Environ Health Perspect 2006;114(2):165-72.
186. Derfus AM, Chan WCW, Bhatia SN. Probing the cytotoxicity of semiconductor quantum dots. Nano Lett 2003;4(1):11-8.
187. Hoshino A, Fujioka K, Oku T, Suga M, Sasaki YF, Ohta T, et al. Physicochemical properties and cellular toxicity of nanocrystal quantum dots depend on their surface modification. Nano Lett 2004;4(11):2163-9.
188. Bao YJ, Li JJ, Wang YT, Yu L, Lou L, Du WJ, et al. Probing cytotoxicity of CdSe and CdSe/CdS quantum dots. Chin Chem Lett 2011;22(7):843-6.
189. Chan W-H, Shiao N-H, Lu P-Z. CdSe quantum dots induce apoptosis in human neuroblastoma cells via mitochondrial-dependent pathways and inhibition of survival signals. Toxicol Lett 2006;167(3):191-200.
190. Su Y, Hu M, Fan C, He Y, Li Q, Li W, et al. The cytotoxicity of CdTe quantum dots and the relative contributions from released cadmium ions and nanoparticle properties. Biomaterials 2010;31(18):4829-34.
191. Hauck TS, Anderson RE, Fischer HC, Newbigging S, Chan WCW. In vivo quantum-dot toxicity assessment. Small 2010;6(1):138-44.
192. Ballou B, Lagerholm BC, Ernst LA, Bruchez MP, Waggoner AS. Noninvasive imaging of quantum dots in mice. Bioconjug Chem 2003;15(1):79-86.
193. Lozano T, et al. Cytotoxicity effects of metal oxide nanoparticles in human tumor cell lines. J Phys Conf Ser 2011;304(1):012046.
194. Chen X, Schluesener HJ. Nanosilver: a nanoproduct in medical application. Toxicol Lett 2008;176(1):1-12.
195. Hutchings GJ, Brust M, Schmidbaur H. Gold-an introductory perspective. Chem Soc Rev 2008;37(9):1759-65.
196. Kuang D, Brillet JRM, Chen P, Takata M, Uchida S, Miura H, et al. Application of highly ordered TiO2 nanotube arrays in flexible dye-sensitized solar cells. ACS Nano 2008;2 (6):1113-6.
197. Drake PL, Hazelwood KJ. Exposure-related health effects of silver and silver compounds: a review. Ann Occup Hyg 2005;49(7):575-85.
198. Chaloupka K, Malam Y, Seifalian AM. Nanosilver as a new generation of nanoproduct in biomedical applications. Trends Biotechnol 2010;28(11):580-8.
199. Tiwari DK, Jin T, Behari J. Dose-dependent in-vivo toxicity assessment of silver nanoparticle in Wistar rats. Toxicol Mech Methods 2011;21(1):13-24.
200. Stebounova L, Adamcakova-Dodd A, Kim J, Park H, O'Shaughnessy P, Grassian V, et al. Nanosilver induces minimal lung toxicity or inflammation in a subacute murine inhalation model. Part Fibre Toxicol 2011;8(1):5.
201. Mohammadkazem K, et al. Assessment of dermal exposure and histopathologic changes of different sized nano-silver in healthy adult rabbits. J Phys Conf Ser 2011;304(1):012028.
202. Liz-Marzán LM. Nanometals: formation and color. Mater Today 2004;7(2):26-31.
203. de la Escosura-Muniz A, Sanchez-Espinel C, Diaz-Freitas B, Gonzalez-Fernandez A, Maltezda Costa M, Merkoci A. Rapid identification and quantification of tumor cells using an electrocatalytic method based on gold nanoparticles. Anal Chem 2009;81(24):10268-74.
204. de la Escosura-Muniz A, Maltez-da Costa M, Sanchez-Espinel C, Diaz-Freitas B, Fernandez-Suarez J, Gonzalez-Fernandez A, et al. Gold nanoparticle-based electrochemical magnetoimmunosensor for rapid detection of anti-hepatitis B virus antibodies in human serum. Biosens Bioelectron 2010;26(4):1710-4.
205. Luo XL, Xu JJ, Du Y, Chen HY. A glucose biosensor based on chitosan-glucose oxidasegold nanoparticles biocomposite formed by one-step electrodeposition. Anal Biochem 2004;334(2):284-9.
206. Khlebtsov N, Dykman L. Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studies. Chem Soc Rev 2011;40(3):1647-71.
207. Semmler-Behnke M, Kreyling WG, Lipka J, Fertsch S, Wenk A, Takenaka S, et al. Biodistribution of 1.4-and 18-nm gold particles in rats. Small 2008;4(12):2108-11.
208. Daoud WA, Xin JH, Zhang Y-H. Surface functionalization of cellulose fibers with titanium dioxide nanoparticles and their combined bactericidal activities. Surf Sci 2005;599 (1-3):69-75.
209. Byrappa K, Ohara S, Adschiri T. Nanoparticles synthesis using supercritical fluid technology-towards biomedical applications. Adv Drug Deliv Rev 2008;60(3):299-327.
210. Xia T, Kovochich M, Liong M, Maüdler L, Gilbert B, Shi H, et al. Comparison of the mechanism of toxicity of zinc oxide and cerium oxide nanoparticles based on dissolution and oxidative stress properties. ACS Nano 2008;2(10):2121-34.
211. Baek M, et al. Factors influencing the cytotoxicity of zinc oxide nanoparticles: particle size and surface charge. J Phys Conf Ser 2011;304(1):012044.
212. Wang J, Zhou G, Chen C, Yu H, Wang T, Ma Y, et al. Acute toxicity and biodistribution of different sized titanium dioxide particles in mice after oral administration. Toxicol Lett 2007;168(2):176-85.
213. Chen J, Dong X, Zhao J, Tang G. In vivo acute toxicity of titanium dioxide nanoparticles to mice after intraperitioneal injection. J Appl Toxicol 2009;29(4):330-7.
214. Fabian E, Landsiedel R, Ma-Hock L, Wiench K, Wohlleben W, van Ravenzwaay B. Tissue distribution and toxicity of intravenously administered titanium dioxide nanoparticles in rats. Arch Toxicol 2008;82(3):151-7.
215. Yokel RA, Florence RL, Unrine JM, Tseng MT, Graham UM, Wu P, et al. Biodistribution and oxidative stress effects of a systemically-introduced commercial ceria engineered nanomaterial. Nanotoxicology 2009;3(3):234-48.
216. Hirst SM, Karakoti A, Singh S, Self W, Tyler R, Seal S, et al. Bio-distribution and in vivo antioxidant effects of cerium oxide nanoparticles in mice. Environ Toxicol 2011. doi: 10.1002/tox.20704
217. Chen J-K, Shih M-H, Peir J-J, Liu C-H, Chou F-I, Lai W-H, et al. The use of radioactive zinc oxide nanoparticles in determination of their tissue concentrations following intravenous administration in mice. Analyst 2010;135(7):1742-6.